- Home
- XERS vs NEO Comparison
XERS vs NEO Comparison
Compare XERS & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- NEO
- Stock Information
- Founded
- XERS 2005
- NEO 2001
- Country
- XERS United States
- NEO United States
- Employees
- XERS N/A
- NEO N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- NEO Precision Instruments
- Sector
- XERS Health Care
- NEO Health Care
- Exchange
- XERS Nasdaq
- NEO Nasdaq
- Market Cap
- XERS 1.3B
- NEO 1.0B
- IPO Year
- XERS 2018
- NEO 1999
- Fundamental
- Price
- XERS $7.36
- NEO $8.08
- Analyst Decision
- XERS Strong Buy
- NEO Buy
- Analyst Count
- XERS 7
- NEO 10
- Target Price
- XERS $8.00
- NEO $12.56
- AVG Volume (30 Days)
- XERS 1.9M
- NEO 2.7M
- Earning Date
- XERS 11-07-2025
- NEO 11-04-2025
- Dividend Yield
- XERS N/A
- NEO N/A
- EPS Growth
- XERS N/A
- NEO N/A
- EPS
- XERS N/A
- NEO N/A
- Revenue
- XERS $246,025,000.00
- NEO $689,189,000.00
- Revenue This Year
- XERS $43.89
- NEO $10.40
- Revenue Next Year
- XERS $20.40
- NEO $10.11
- P/E Ratio
- XERS N/A
- NEO N/A
- Revenue Growth
- XERS 35.62
- NEO 9.70
- 52 Week Low
- XERS $2.69
- NEO $4.72
- 52 Week High
- XERS $8.03
- NEO $19.12
- Technical
- Relative Strength Index (RSI)
- XERS 51.35
- NEO 59.90
- Support Level
- XERS $7.56
- NEO $7.36
- Resistance Level
- XERS $7.89
- NEO $8.42
- Average True Range (ATR)
- XERS 0.24
- NEO 0.48
- MACD
- XERS -0.14
- NEO 0.02
- Stochastic Oscillator
- XERS 2.90
- NEO 63.02
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.